Biocon’s Drug Substance Facility in Bangalore completes U.S. FDA Inspection with No observations

Bengaluru, India, September 22, 2018

“This is to inform you that the U.S. FDA conducted a periodic cGMP inspection of our Drug Substance manufacturing site at Bangalore Campus from Sep 17 - 21, 2018. The weeklong audit concluded without any observations and no Form 483 was issued. The successful audit of this site reflects our strong commitment to cGMP compliance.”  -Company Spokesperson